Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and related disorders.

The FDA is set to make a final decision in July 2023, and if approved, lecanemab would join aducanumab as the only antiamyloid therapies available to treat early-stage Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 9, 2023.

According to a recent study presented at SLEEP 2023, the decline in MOCA scores in patients with mild cognitive impairment was associated with the degree of hypoxia observed from sleep studies.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Sleep Medicine.

Neurofilament light, a biomarker elevated in neurodegeneration and dementia, was higher among poor sleepers with Pittsburgh Sleep Quality Index scores of less than 5.

Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 2, 2023.

In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.

The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

Using trials selected by amyloid positivity, amyloid-targeting therapies had slightly greater efficacy in APOE ε4 carriers than in noncarriers.

Robust, sustained reductions in key pharmacodynamic biomarker were observed; however, this did not lead to functional benefits on any of the scales used in the trial.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep and sleep disorders.

Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

Over a 4-month treatment period, the agent was well tolerated, with patients showing no significant changes in ADAS-Cog or CDR-SB scores, indicating no cognitive decline.

Regardless of highly different demographics and smaller sample size, the association between amyloid in the brain and plasma was influenced by overall vascular risk score, and was only consistently observed in APOE ɛ4 carriers.

Here's some of what is coming soon to NeurologyLive® this week.

At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]